- Home
- ACM vs PTGX Comparison
ACM vs PTGX Comparison
Compare ACM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACM | PTGX |
|---|---|---|
| Founded | 1980 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.5B |
| IPO Year | 2007 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ACM | PTGX |
|---|---|---|
| Price | $74.66 | $135.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $131.30 | $108.23 |
| AVG Volume (30 Days) | ★ 1.4M | 602.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 42.71 | N/A |
| EPS | ★ 1.95 | 0.05 |
| Revenue | ★ $16,139,622,000.00 | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $6.06 | N/A |
| P/E Ratio | ★ $37.12 | $2,732.80 |
| Revenue Growth | ★ 0.21 | N/A |
| 52 Week Low | $66.28 | $50.49 |
| 52 Week High | $135.52 | $143.29 |
Technical Indicators
Market Signals| Indicator | ACM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 53.58 |
| Support Level | $67.49 | $94.48 |
| Resistance Level | $86.74 | $142.20 |
| Average True Range (ATR) | 1.99 | 6.54 |
| MACD | 0.69 | -1.12 |
| Stochastic Oscillator | 89.97 | 41.36 |
Price Performance
Historical ComparisonAbout ACM AECOM
Aecom is one of the largest global providers of advisory, design, and engineering services. It serves a broad spectrum of end markets, including water, transportation, and environment. Based in Dallas, Aecom employs 51,000 people. The company generated $16.1 billion in sales in fiscal 2025.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.